United Therapeutics Corporation (NASDAQ:UTHR) Director Christopher Causey sold 580 shares of the stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $134.48, for a total value of $77,998.40. Following the completion of the sale, the director now owns 3,295 shares in the company, valued at approximately $443,111.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Christopher Causey also recently made the following trade(s):

  • On Thursday, July 6th, Christopher Causey sold 590 shares of United Therapeutics Corporation stock. The shares were sold at an average price of $132.61, for a total value of $78,239.90.

United Therapeutics Corporation (NASDAQ:UTHR) traded down 1.12% on Thursday, hitting $133.52. The stock had a trading volume of 915,749 shares. The company’s 50 day moving average price is $130.34 and its 200 day moving average price is $130.91. The firm has a market cap of $5.80 billion, a price-to-earnings ratio of 15.48 and a beta of 1.52. United Therapeutics Corporation has a 52-week low of $110.90 and a 52-week high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of $3.61 by $4.86. The business had revenue of $444.60 million for the quarter, compared to analysts’ expectations of $391.53 million. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.42 earnings per share. Analysts expect that United Therapeutics Corporation will post $10.09 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Christopher Causey Sells 580 Shares of United Therapeutics Corporation (UTHR) Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/07/christopher-causey-sells-580-shares-of-united-therapeutics-corporation-uthr-stock.html.

A number of equities research analysts have weighed in on the company. Jefferies Group LLC restated a “sell” rating and set a $105.00 price target on shares of United Therapeutics Corporation in a research report on Thursday, June 8th. BidaskClub downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. ValuEngine downgraded United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. UBS AG restated a “sell” rating and set a $106.00 price target on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. Finally, Zacks Investment Research downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Six investment analysts have rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the stock. United Therapeutics Corporation presently has a consensus rating of “Hold” and an average target price of $134.50.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Focused Wealth Management Inc raised its position in shares of United Therapeutics Corporation by 17.5% during the 1st quarter. Focused Wealth Management Inc now owns 940 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 140 shares in the last quarter. Advisory Services Network LLC purchased a new stake in shares of United Therapeutics Corporation during the 1st quarter valued at about $147,000. Daiwa Securities Group Inc. raised its position in shares of United Therapeutics Corporation by 17.4% during the 1st quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 200 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new stake in shares of United Therapeutics Corporation during the 1st quarter valued at about $204,000. Finally, Eagle Global Advisors LLC purchased a new stake in shares of United Therapeutics Corporation during the 2nd quarter valued at about $206,000.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.